All articles by Swagath Bandhakavi
Swagath Bandhakavi
J&J’s Darzalex Faspro regimen wins FDA approval for NDMM treatment
The approval is for the induction and consolidation treatment of patients with newly diagnosed multiple myeloma who qualify for an autologous stem cell transplant
AstraZeneca reports Calquence plus venetoclax combo improves PFS in Phase 3 CLL trial
The AMPLIFY trial showed that the combination significantly improved PFS compared to standard chemoimmunotherapy in previously untreated patients
Innovent Biologics partners with WeComput to enhance AI-driven drug discovery
Through this collaboration, both parties will leverage their respective strengths and technologies to expedite the drug discovery and development process using AI technology
EC approves AbbVie’s Skyrizi for ulcerative colitis treatment
The approval applies to individuals who have had an inadequate response to, lost response to, or were intolerant to conventional or biologic therapy
Luye Pharma announces FDA approval of ERZOFRI extended-release injectable suspension for treating schizophrenia and schizoaffective disorder
Both schizophrenia and schizoaffective disorder are severe, chronic psychiatric disorders characterised by recurring relapses
TRxADE HEALTH completes all-stock merger deal with Scienture
Scienture specialises in developing specialty product concepts and solutions that enhance value for patients and healthcare systems
Novo Nordisk’s Wegovy receives positive opinion from EMA’s CHMP for label update
The update incorporates data from the SELECT cardiovascular outcomes trial, which showed a reduction in the risk of major adverse cardiovascular events
Sage Therapeutics and Biogen halt clinical development of SAGE-324 for essential tremor
In a mid-stage study, the oral drug candidate could not show a statistically significant dose-response relationship in treating the neurological disorder
UK approves Novo Nordisk’s semaglutide to prevent cardiovascular events in obese adults
The MHRA’s latest approval designates semaglutide as the first weight loss drug to be prescribed for the prevention of cardiovascular events, including cardiovascular death, non-fatal heart attack, and non-fatal stroke
Samsung Bioepis’ EPYSQLI gets FDA approval as biosimilar to Soliris
The approval permits the use of EPYSQLI for the treatment of patients with paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome